Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 260

Sort by

Sort Order Select

Journal Articles

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 864.

https://doi.org/10.1182/blood-2024-194627

Published: 2024

Journal Articles

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Jennifer J. Huang, Namrata Singh, Mazyar Shadman, Ryan S. Basom, Andrea Kalus, Andrew J Portuguese, Emily C Liang, Natalie Wuliji, Alexandre V. Vinaud Hirayama, Aude G Chapuis, Folashade Otegbeye, Filippo Milano, Ryan D. Cassaday, Ajay K. Gopal, Brian G. Till, Edus H. Warren, Jordan Gauthier, Lawrence Fong, David G. Maloney

Blood (2024) 144 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2024-201809

Published: 2024

Journal Articles

TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

Erik L Kimble, Salvatore Fiorenza, Alexandre V. Vinaud Hirayama, Austin M Gabel, Jordan Gauthier, Aiko Torkelson, Abigail Chutnik, Henna Di, Jocelyn H Wright, Barbara Pender, Stefan Radtke, Roland B. Walter, Hans-Peter Kiem, David G. Maloney, Robert K. Bradley, Cameron J. Turtle

Blood (2024) 144 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2024-207966

Published: 2024

Journal Articles

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Salvatore Fiorenza, Yue Cao, Ye Zheng, Janaki Purushe, Tamara Bock, Erik L Kimble, Derek Janssens, Delaney Kirchmeier, Alexandre V. Vinaud Hirayama, Jordan Gauthier, David G. Maloney, Stanley R. Riddell, Akira Nguyen-Shaw, Steven Henikoff, Jean Yang, Cameron J. Turtle

Blood (2024) 144 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2024-200589

Published: 2024

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Blood (2024) 144 (Supplement 1): 4832.

https://doi.org/10.1182/blood-2024-205942

Published: 2024

Journal Articles

Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

Andrew J Portuguese, Mahnoosh Taheri, Rahul Banerjee, Kara I. Cicero, Mary Kwok, Natalie Wuliji, Lorenzo Iovino, Alexandre V. Vinaud Hirayama, Erik L Kimble, Leona Holmberg, Mazyar Shadman, Jordan Gauthier, David G. Maloney, Andrew J. Cowan

Blood (2024) 144 (Supplement 1): 3772.

https://doi.org/10.1182/blood-2024-201092

Published: 2024

Journal Articles

HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

Blood (2024) 144 (10): 1069–1082.

https://doi.org/10.1182/blood.2024024105

Published: 2024

Includes: Supplemental data

Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Blood (2024) 143 (6): 496–506.

https://doi.org/10.1182/blood.2023021243

Published: 2024

Includes: Supplemental data

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL

Laura Samples, Chaitra S Ujjani, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Stephanie Louie, Christina Poh, Stephen D Smith, Brian G Till, David G Maloney, Ajay K Gopal, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2023-187129

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Journal Articles

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Ilaria Romano, Jordan Gauthier, Ryan C Lynch, Ajay K Gopal, Alexandre V Hirayama, Kikkeri N Naresh, Alireza Torabi, Stephen D Smith, Brian G Till, David G Maloney, Chaitra S Ujjani, Christina Poh, Filippo Milano, Aude G Chapuis, Mazyar Shadman, Lorenzo Iovino

Blood (2023) 142 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2023-181956

Published: 2023

Journal Articles

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

Laura Samples, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Hania Shakalia, Stephanie Louie, David G Maloney, Christina Poh, Brian G Till, Stephen D Smith, Ajay K Gopal, Chaitra S Ujjani, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2023-186775

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Salvatore Fiorenza, Ye Zheng, Jay Sarthy, Alyssa Sheih, Erik L Kimble, Delaney Kirchmeier, Derek Janssens, Tinh-Doan Phi, Jordan Gauthier, Alexandre V Hirayama, Qian Wu, Raphael Gottardo, Stanley R. Riddell, David G Maloney, Steven Henikoff, Cameron J. Turtle

Blood (2023) 142 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2023-188269

Published: 2023

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Blood (2023) 142 (Supplement 1): 330.

https://doi.org/10.1182/blood-2023-179529

Published: 2023

Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Blood (2023) 142 (Supplement 1): 4868.

https://doi.org/10.1182/blood-2023-174914

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

NARROW

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only